Back to News
Market Impact: 0.2
VivoSim Labs Presents New NAMkind Data At EUROTOX 2026
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
VivoSim Labs presented new NAMkind platform data at EUROTOX 2026 in Vienna, highlighting the platform's potential to predict drug toxicity using 3D human liver and intestinal tissue models. The announcement supports the company's technology-validation narrative, though the article provides no quantitative results, commercial milestones, or financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
VIVS0.45
More News
- Companies promised AI gains— here's how the payoff showed up in earnings
- U.S workers just took home their smallest share of capital since at least 1947—and the lowest ever recorded
- Fears over $828 billion AI capex spending spree help erase $1 trillion in market value
- Intel stock plunges 29%. Analysts urge caution on buying the dip
- How Ambani’s Jio became India’s second-largest company
- OpenAI pares fundraising goal, now seeking up to $20 billion in latest round